Peter Morrison

About Peter Morrison

I serve as the leader of the Los Angeles Litigation Group, co-head of the West Coast litigation practice and one of the hiring partners for Skadden’s Los Angeles office. I have a broad litigation practice with a particular emphasis on securities, M&A and tax litigation. I advise corporations on matters involving both federal and state securities laws, duties of corporate directors, SEC and stock exchange inquiries and investigations, contests for corporate control and tax reporting. In 2022, I was named among Daily Journal\'s Top 100 attorneys, in addition to being named a Top Litigator and Trial Lawyer in Los Angeles by the Los Angeles Business Journal in 2021 and 2019. In 2018, I was named Lawyer of the Year for Litigation – Securities, Los Angeles by The Best Lawyers in America. I also have been selected for inclusion in Chambers USA: America’s Leading Lawyers for Business since 2016 and The Best Lawyers in America since 2014. For three consecutive years (2011-13), I was named to Law360’s list of Rising Stars.In certain jurisdictions, this may be considered attorney advertising.

Experience

1. Partner

   Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates

   Nov 2000 — Present · Los Angeles, CA, US

   Notable representations include- The We Company and certain of its current and former directors in two putative shareholder class action and derivative lawsuits stemming from the company\'s withdrawn 2019 initial public offering, a disputed tender offer involving the company\'s largest investor and certain past conduct by the company\'s former CEO- American Apparel, Inc. in connection with securities class actions and derivative lawsuits brought in federal and state court in California- certain former outside directors of Countrywide Financial Corporation in securities, derivative and ERISA litigations- Questcor Pharmaceuticals, Inc.(now Mallinckrodt Pharmaceuticals) in federal securities class action and derivative litigation in Los Angeles alleging misrepresentations concerning, among other things, the effectiveness of the company’s flagship product and prospects for growth- Ripple Labs Inc. in a putative class action alleging that it should have registered its virtual currency XRP as a security under federal securities laws- Centene Corp. in a putative federal securities fraud class action arising out of its $6.8 billion acquisition of Health Net, Inc- Valeant Pharmaceuticals International and certain of its directors and officers in class action lawsuits in California and Delaware brought by shareholders in connection with the proposed $3.3 billion merger of Valeant and Biovail- Asterias Biotherapeutics, Inc. in securing the dismissal of a California state lawsuit arising out of the company’s merger with BioTime (now known as Lineage), and in a related matter currently pending in the Delaware Court of Chancery- Oakley, Inc. and its board of directors in a lawsuit brought by one of the company\'s shareholders seeking to enjoin the $2 billion acquisition of Oakley by Luxottica Group S.p.A; and- KPMG in multiple actions involving claims ranging from fraud, negligence and contract enforcement to constitutional violations.

Education

• University of Pennsylvania

  Bachelor of Arts (B.A.)

  1992 — 1996

• New York University School of Law

  Doctor of Law (J.D.)

  1996 — 1999